Hiroi Kasai

A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer

Tomonori Yano, Hiroi Kasai, Takahiro Horimatsu et al. · Oncotarget · 2016 · 122 citations · Full text

Medicine, Oncology, Radiation Oncology +14

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano et al. · Breast Cancer Research and Treatment · 2020 · 57 citations · Full text

Medicine, Oncology, Pharmacology +16

Preclinical Validation of Talaporfin Sodium-Mediated Photodynamic Therapy for Esophageal Squamous Cell Carcinoma

Shinya Ohashi, Osamu Kikuchi, Mihoko Tsurumaki et al. · PLoS ONE · 2014 · 29 citations · Full text

Medicine, Oncology, Pharmacology +16

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial

Norikazu Masuda, Hiroko Bando, Takashi Yamanaka et al. · Breast Cancer Research and Treatment · 2021 · 22 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer

Seigo Nakamura, Masashi Ando, Norikazu Masuda et al. · Clinical Breast Cancer · 2011 · 13 citations

Medicine, Oncology, Pharmacology +16